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Treatment for acute hepatitis B is recommended in order to reduce the risk of progression to fulminant hepatitis 
and the need of OLT. We report our experience on treatment with high dose lamivudine, in patients with severe 
acute HBV infection. The diagnosis was based on clinical and virological findings and exclusion of other known 
causes of liver damage. The decision to treat was based on the prolongation of INR together with increasing 
values of bilirubin and ALT. Four patients received Lamivudine 200 mg/daily until clearance of serum 
HBV-DNA and then 100 mg/daily until clearance of HBsAg and appearance of anti-HBs antibodies. One patient 
received 100 mg/daily because of chronic renal impairment. The median period of hospitalization was 13 days, 
and none of the patients had complications, related either to underlying disease or to therapy. The complete 
normalization of serum transaminases and bilirubin occurred on average after 5.5 weeks and 3 weeks respec-
tively. All patients cleared serum HBV-DNA within three months, lost HBeAg and HBsAg and seroconverted to 
anti-HBe; four patients developed anti-HBs at a protective titre. Early antiviral treatment attenuates the clinical 
and biochemical impairment leading to fast healing and promoting complete recovery. 
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Introduction 
The incidence of acute hepatitis B (HBV) is largely 
reduced during the last 20 years as a result of the use of 
vaccination and routine blood donor screening [1] and, 
nowadays, in western countries, the risk of HBV infec-
tion is limited to sexual intercourses, intravenous drug 
users and, in a few cases, in patients undergoing dental 
therapy, acupuncture, piercing and tattooing [2-4]. 
Acute HBV may still occur in adults and may result in 
fatal complications. Most symptomatic patients re-
cover and treatment is not necessary; when there are 
signs of severe liver failure, treatment is recommended 
in order to reduce the risk of progression to fulminant 
or subfulminant hepatitis and the need of emergency 
liver transplantation [5]. 
The experience on acute HBV treatment is limited 
and controversial. A randomised controlled trial on 
standard interferon versus placebo shows greater HBs 
seroconversion in patients treated with 10 MU/TIW [6]. 
With regard to lamivudine, studies with a limited 
number of patients and case reports are encouraging 
[7-9] while the only randomised controlled study avail-
able does not show a significant clinical and bio-
chemical improvement compared to placebo at a dose 
of 100 mg/daily [10]. 
We report our experience on treatment with high 
dose lamivudine, in a series of 5 patients with severe 
acute HBV infection. 
Patients and Methods 
From November 2006 to March 2007, 5 patients 
with acute HBV related hepatitis were admitted to our 
department: 4 patients were HBeAg positive and 1 anti 
HBe positive. The diagnosis was based on consistent 
clinical and virological findings (medical history, 
jaundice, hypertransaminasemia, HBsAg positivity, 
IgM anti-HBc > 1.20 mU/mL and presence of serum 
HBV-DNA by PCR) and exclusion of other known 
causes of liver damage. Baseline characteristics of pa-
tients are shown in table 1. All patients underwent 
ultrasonography guided liver biopsy to confirm the 
diagnosis.  
Treatment 
The decision to treat was based on the prolonga-
tion of INR together with increasing values of bilirubin 
and ALT. 
Four patients received Lamivudine 200 mg/daily 
until clearance of serum HBV-DNA was reached and Int. J. Med. Sci. 2008, 5 
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then 100 mg/daily until resolution (clearance of 
HBsAg and appearance of anti-HBs antibodies). One 
patient received 100 mg/daily because of renal im-
pairment (creatinine clearance 32 ml/min). Patients 
were followed up for at least six months (range: 6-11 
months) after the end of treatment. 
Table 1: Baseline characteristics of patients. 
Characteristics  n = 5 
Sex (M:F)  4:1 (80%) 
Age  45 (33 – 64) 
Hepatic encephalopathy (I-II°)  2/5 (40%) 
Bilirubin (mg/dL)  26,28  (23,4-45,1) 
ALT (IU/L)   2494 (1472-3260) 
INR   1,47 (1,4–1,51) 
HBeAg positive  4 (80%) 
HBeAb positive  1 (20%) 
HBV-DNA (log IU/mL)  6,7 (4,9–8,6) 
 
Results are expressed as median (range). 
Results  
The median period of hospitalization was 13 days 
(12-15) and no patient had complications, both related 
to underlying disease or to therapy.  
We observed a prompt decrease of ALT (-1399 IU/L in 
a week, -2120 IU/L in two weeks) and serum bilirubin 
(-15 mg in a week, -23.9 mg in two weeks). The com-
plete normalization of transaminases and bilirubine-
mia occurred on average after 5.5 weeks and 3 weeks, 
respectively. 
All HBeAg+ patients lost e-antigen and serocon-
verted to anti HBe; they lost HBsAg within six months 
from the start of treatment and 4/5 developed 
anti-HBs at a protective titre (>10 mU/mL). 
We observed an average drop of HBV-DNA of 
1.58 logarithms in a week and 3.38 logarithms in two 
weeks. All patients cleared HBV-DNA (evaluated by 
PCR) in two months on average. 
There were no adverse reactions to medication 
which was well tolerated. 
Discussion 
Differently from previous studies, we have cho-
sen to treat acute hepatitis B with a higher dose of 
lamivudine (200 mg/day instead of 100mg/day) 
achieving a rapid viral clearance and clinical im-
provement. All patients were discharged by the hos-
pital, in spite of disease severity at presentation, within 
13 days from the start of oral antiviral treatment. 
From our data, treatment with nucleoside ana-
logues for severe and fulminant hepatitis B (acute or 
exacerbation of a chronic infection) is certainly indi-
cated. In fact, early antiviral treatment shortens and 
improves the symptomatic phase of infection and al-
lows a ready clinical and biochemical improvement. 
On the other hand, when patients with end stage liver 
disease are treated with nucleoside analogues, the 
dramatic improvement of hepatic function often leads 
to withdrawal from the liver transplantation list. 
In our experience, lamivudine administration did 
not favour, as previously suggested by Kumar et al., 
the development of a chronic infection, since all pa-
tients displayed undetectable HBV-DNA and cleared 
HBsAg. 
Severe or fulminant acute hepatitis B generally do 
not evolve to a chronic disease, since the immune re-
sponse that causes liver damage also leads to the viral 
clearance. In this setting, with the use of nucleoside 
analogues we obtained a prompt hepatic biochemical 
and functional improvement and a strong suppression 
of viral replication, which probably enforced the on-
going process of recovery. Furthermore, we reduced 
the risk of fatal outcome which can occur in some of 
these patients.  
With the use of a double dose of lamivudine (200 
mg/day) we obtained a decrease of viral load even 
faster than observed in previous studies: in fact we 
observed an average decrease of serum HBV-DNA of 
3.38 log IU/mL in the first two weeks of treatment, 
respect to 1 log decrease in one month reported by 
other authors [11]. 
To the best of our knowledge, only the studies of 
Tillman et al. and by Kumar et al. had a control 
group[10,11]. From those studies two major results 
emerge: the number of responders (HBV-DNA nega-
tive) is higher in the treated group compared to con-
trols (91.6% against 71.6%). Even though not statisti-
cally significant, this figure outlines a trend and should 
not be underestimated. Furthermore, the number of 
adverse events (death and transplantation) was sig-
nificantly lower in both studies in the treated groups 
(5.2% against 21.6% in controls). The lack of a control 
group is certainly a limitation but according to recent 
guidelines treatment is indicated for patients with 
fulminant hepatitis B and those with protracted, severe 
acute hepatitis B; therefore, a control group in this set-
ting would likely not be judged ethical. 
Many authors have suggested the need for a large 
placebo-controlled study. However, in light of our 
results and from data previously published, the only 
ethical choice in patients with severe and fulminant 
acute hepatitis B seems to be the treatment with oral 
antiviral drugs. 
On the basis of our results we suggest that, with 
regard to lamivudine, a higher dose provides an effec-
tive and fast healing of severe acute hepatitis. 
Despite the low genetic barrier of lamivudine, we 
chose it because at that time it was the drug with the 
fastest antiviral activity among those available.  Int. J. Med. Sci. 2008, 5 
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It is conceivable that new available drugs for the 
treatment of hepatitis B (i.e. entecavir and telbivudine) 
might be even better in reaching a rapid decrease in 
viral load and a faster recovery in patients with ful-
minant or severe acute hepatitis. 
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Figure 1: Fall of viral load and biochemical response during high dose lamivudine therapy. 
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Table 2: Time(days) to virological seroconversion and bio-
chemical normalization. 
Time to Virological Seroconversion and Biochemical Normaliza-
tion 
 Patients     
  # 1  # 2  # 3  # 4  # 5  Mean 
(days) 
HBV-DNA-ve  30 30 90 90 30 54±14.7 
HBsAg  –ve  60 30 90 90 30 60±13.4 
anti-HBs  >10  60 30 90 /  30 52.5±14.4 
anti-HBs  >100  90 60 180  /  90 105±25.9 
Bilirubin  30 15 30 15 15 21±3.7 
ALT  45 45 45 30 30 39±3.7 
INR  13 12 15 16 12 13.6±0.8 
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